TP53 and cancer: The subgroups associated with a poor prognosis (low TMB, age ≤ 65 years, PIK3CA-WT, ARID1A-WT, and TP53-MT) were enriched for FGFR, MET and other cancer-promoting pathways, such as NOTCH, JAK-STAT, PI3K-Akt, and angiogenesis.